doi:10.3969/j.issn.1004-583X.2021.11.016

Abstract

CLC Number:

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2021.11.016

https://huicui.hebmu.edu.cn/EN/Y2021/V36/I11/1041

References 41

[1]	中国心血管健康与疾病报告编写组. 中国心血管健康与疾病报告2019概要[J]. 中国循环杂志, 2020, 35(9):833-854.
[2]	Ambrosy AP, Fonarow GC, Butler J, et al. The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries[J]. J Am Coll Cardiol, 2014, 63(12):1123-1133. doi: S0735-1097(14)00291-5 pmid: 24491689
[3]	Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications[J]. Circulation, 1990, 81(4):1161-1172. doi: 10.1161/01.cir.81.4.1161 pmid: 2138525
[4]	李崇耀, 张曼, 赵鸿斌, 等. 沙库巴曲缬沙坦联合芪苈强心胶囊治疗慢性心力衰竭患者的临床疗效观察[J]. 疑难病杂志, 2020, 19(7):667-671.
[5]	刘岳, 汪芳. 沙库巴曲缬沙坦的药代动力学和药效学特点[J]. 中国循环杂志, 2018, 33(2):198-200.
[6]	Rodgers JE. Sacubitril/valsartan: The newest addition to the toolbox foe guideline-directed medical therapy of heart failure[J]. Am J Med, 2017, 130(6):635-639. doi: S0002-9343(17)30216-4 pmid: 28285069
[7]	McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure[J]. N Engl J Med, 2014, 371(11):993-1004. doi: 10.1056/NEJMoa1409077 URL
[8]	Yandrapalli S, Khan MH, Rochlani Y, et al. Sacubitril/valsartan in cardiovascular disease: evidence to date and place in therapy[J]. Ther Adv Cardiovasc Dis, 2018, 12(8):217-231. doi: 10.1177/1753944718784536 pmid: 29921166
[9]	Kang DH, Park SJ, Shin SH, et al. Angiotensin receptor neprilysin inhibitor for functional mitral regurgitation[J]. Circulation, 2019, 139(11):1354-1365. doi: 10.1161/CIRCULATIONAHA.118.037077 URL
[10]	Januzzi JL, Prescott MF, Butler J, et al. Association of change in N-terminal pro-B-type natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction[J]. JAMA, 2019, 322(11):1085-1095. doi: 10.1001/jama.2019.12821 URL
[11]	Wachter R, Senni M, Belohlavek J, et al. Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: Primary results of the randomised TRANSITION study[J]. Eur J Heart Fail, 2019, 21(8):998-1007. doi: 10.1002/ejhf.1498 pmid: 31134724
[12]	Velazquez EJ, Morrow DA, DeVore AD, et al. Angiotensin-neprilysin inhibition in acute decompensated heart failure[J]. N Engl J Med, 2019, 380(6):539-548. doi: 10.1056/NEJMoa1812851 URL
[13]	Solomon SD, Zile M, Pieske B, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: A phase 2 double-blind randomised controlled trial[J]. Lancet, 2012, 380(9851):1387-1395. doi: 10.1016/S0140-6736(12)61227-6 pmid: 22932717
[14]	Solomon SD, McMurray JJV, Anand IS, et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction[J]. N Engl J Med, 2019, 381(17):1609-1620. doi: 10.1056/NEJMoa1908655 URL
[15]	Solomon SD, Vaduganathan M, L Claggett B, et al. Sacubitril/valsartan across the spectrum of ejection fraction in heart failure[J]. Circulation, 2020, 141(5):352-361. doi: 10.1161/CIRCULATIONAHA.119.044586 pmid: 31736342
[16]	McMurray JJV, Jackson AM, Lam CSP, et al. Effects of sacubitril-valsartan versus valsartan in women compared with men with heart failure and preserved ejection fraction: Insights from PARAGON-HF[J]. Circulation, 2020, 141(5):338-351. doi: 10.1161/CIRCULATIONAHA.119.044491 pmid: 31736337
[17]	Wachter R, Shah SJ, Cowie MR, et al. Angiotensin receptor neprilysin inhibition versus individualized RAAS blockade: Design and rationale of the PARALLAX trial[J]. ESC Heart Fail, 2020, 7(3):856-864. doi: 10.1002/ehf2.12694 pmid: 32297449
[18]	Selvaraj S, Claggett BL, Packer M, et al. Effects of Sacubitril/valsartan on serum lipids in heart failure with preserved ejection fraction[J]. J Am Heart Assoc, 2021, 16:e022069.
[19]	Mc Causland FR, Lefkowitz MP, Claggett B, et al. Angiotensin-neprilysin inhibition and renal outcomes in heart failure with preserved ejection fraction[J]. Circulation, 2020, 142(13):1236-1245. doi: 10.1161/CIRCULATIONAHA.120.047643 pmid: 32845715
[20]	Qureshi WT, Zhang ZM, Chang PP, et al. Silent myocardial infarction and long-term risk of heart failure: The ARIC study[J]. J Am Coll Cardiol, 2018, 71(1):1-8. doi: S0735-1097(17)41438-0 pmid: 29301615
[21]	Torrado J, Cain CK, Mauro AG, et al. Sacubitril/Valsartan averts adverse post-infarction ventricular remodeling and preserves systolic function in rabbits[J]. J Am Coll Cardiol, 2018, 72(19):2342-2356. doi: S0735-1097(18)38437-7 pmid: 30384891
[22]	Ishii M, Kaikita K, Sato K, et al. Cardioprotective effects of LCZ696 (sacubitril/valsartan) after experimental acute myocardial infarction[J]. JACC Basic Transl Sci, 2017, 2(6):655-668.
[23]	Zhang Y, Wu Y, Zhang K, et al. Benefits of early administration of sacubitril/valsartan in patients with ST-elevation myocardial infarction after primary percutaneous coronary intervention[J]. Coron Artery Dis, 2021, 32(5):427-431. doi: 10.1097/MCA.0000000000000955 URL
[24]	Rezq A, Saad M, El Nozahi M. Comparison of the efficacy and safety of sacubitril/valsartan versus ramipril in patients with ST-segment elevation myocardial infarction[J]. Am J Cardiol, 2021, 143:7-13. doi: 10.1016/j.amjcard.2020.12.037 URL
[25]	Jering KS, Claggett B, Pfeffer MA, et al. Prospective ARNI versus ACE inhibitor trial to determIne superiority in reducing heart failure events after myocardial infarction (PARADISE-MI): Design and baseline characteristics[J]. Eur J Heart Fail, 2021, 23(6):1040-1048. doi: 10.1002/ejhf.v23.6 URL
[26]	Williams B, Cockcroft JR, Kario K, et al. Effects of sacubitril/valsartan versus olmesartan on central hemodynamics in the elderly with systolic hypertension: The PARAMETER study[J]. Hypertension, 2017, 69(3):411-420. doi: 10.1161/HYPERTENSIONAHA.116.08556 pmid: 28093466
[27]	Williams B, Lacy PS, Baschiera F, et al. Novel description of the 24-hour circadian rhythms of brachial versus central aortic blood pressure and the impact of blood pressure treatment in a randomized controlled clinical trial: The ambulatory central aortic pressure (AmCAP) study[J]. Hypertension, 2013, 61(6):1168-1176. doi: 10.1161/HYPERTENSIONAHA.111.00763 pmid: 23630950
[28]	Zheng L, Xia B, Zhang X, et al. A meta-analysis on the effect and safety of LCZ696 in the treatment of hypertension[J]. Cardiol Res Pract, 2021, 2021(1):1-10.
[29]	Wang TD, Tan RS, Lee HY, et al. Effects of sacubitril/valsartan (LCZ696) on natriuresis, diuresis, blood pressures, and NT-proBNP in salt-sensitive hypertension[J]. Hypertension, 2017, 69(1):32-41. doi: 10.1161/HYPERTENSIONAHA.116.08484 URL
[30]	Kario K, Tamaki Y, Okino N, et al. LCZ696, a first-in-class angiotensin receptor-neprilysin inhibitor: The first clinical experience in patients with severe hypertension[J]. J Clin Hypertens (Greenwich), 2016, 18(4):308-314. doi: 10.1111/jch.12667 URL
[31]	Ito S, Satoh M, Tamaki Y, et al. Safety and efficacy of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension and renal dysfunction[J]. Hypertens Res, 2015, 38(4):269-275. doi: 10.1038/hr.2015.1 URL
[32]	Martens P, Nuyens D, Rivero-Ayerza M, et al. Sacubitril/valsartan reduces ventricular arrhythmias in parallel with left ventricular reverse remodeling in heart failure with reduced ejection fraction[J]. Clin Res Cardiol, 2019, 108(10):1074-1082. doi: 10.1007/s00392-019-01440-y pmid: 30788621
[33]	Chang PC, Wo HT, Lee HL, et al. Sacubitril/valsartan therapy ameliorates ventricular tachyarrhythmia inducibility in a rabbit myocardial infarction model-science direct[J]. J Card Fail, 2020, 26(6):527-537. doi: 10.1016/j.cardfail.2020.03.007 URL
[34]	李倩, 李昕, 李路安, 等. 沙库巴曲缬沙坦通过逆转高血压大鼠心房结构重塑降低房颤易感性[J]. 中国药理学通报, 2021, 37(5):631-637.
[35]	王涛, 易登良, 范忠才. 沙库巴曲缬沙坦对糖尿病心肌病大鼠的保护作用及其机制[J]. 西安交通大学学报(医学版), 2021, 42(1):42-47.
[36]	Kim HM, Kim KH, Park JS, et al. Beneficial effect of left ventricular remodeling after early change of sacubitril/valsartan in patients with nonischemic dilated cardiomyopathy[J]. Medicina (Kaunas), 2021, 57(5):416.
[37]	Tafelmeier M, Baessler A, Wagner S, et al. Design of the SILICOFCM study: effect of sacubitril/valsartan vs lifestyle intervention on functional capacity in patients with hypertrophic cardiomyopathy[J]. Clin Cardiol, 2020, 43(5):430-440. doi: 10.1002/clc.23346 pmid: 32125709
[38]	Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)[J]. Eur Heart J, 2016, 37(27):2129-2200. doi: 10.1093/eurheartj/ehw128 pmid: 27206819
[39]	Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: areport of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America[J]. J Card Fail, 2017, 23(8):628-651. doi: 10.1016/j.cardfail.2017.04.014 URL
[40]	王华, 梁延春. 中国心力衰竭诊断和治疗指南2018[J]. 中华心血管病杂志, 2018, 46(10):760-789.
[41]	Seferovic PM, Ponikowski P, Anker SD, et al. Clinical practice update on heart failure 2019: Pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology[J]. Eur J Heart Fail, 2019, 21(10):1169-1186. doi: 10.1002/ejhf.1531 pmid: 31129923

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 41

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	. [J]. Clinical Focus, 2024, 39(2): 188-192.
[2]	Huang Yuling, Zhang Xinyue, Rong Pingping, Yang Wenqi, Cao Xinying, Xing Cainai, Wang Zhijun, Liu Ning. Correlation analysis of Non-HDL-C/HDL-C and NHR with the severity of coronary artery disease [J]. Clinical Focus, 2024, 39(2): 115-120.
[3]	Wang Yihan, Qin Xuyan, Han Xuanze, Wang Yingjie, Gao Feifei, Chen Chunhong, Zhang Lingnan, Zhang Fang. Efficacy and safety of rivaroxaban therapy in elderly patients with non-valvular atrial fibrillation who had a HASBLED score≥3 [J]. Clinical Focus, 2024, 39(2): 121-124.
[4]	. [J]. Clinical Focus, 2024, 39(2): 168-171.
[5]	. [J]. Clinical Focus, 2024, 39(1): 75-79.
[6]	. [J]. Clinical Focus, 2024, 39(1): 80-83.
[7]	Liu Yi, Cui Kun, Liu Chang, Zhao Haotian, Li Li, Xue Hongyuan. Correlation between serum secreted frizzled-related protein 5 and early renal damage in patients with essential hypertension [J]. Clinical Focus, 2023, 38(12): 1073-1077.
[8]	Jiang Ji, Zhu Xiaogang, Jiang Shan, Dawa Zhaba, Cen Qiang. Risk factors of proteinuria in hypertensive people living at high altitude for generations [J]. Clinical Focus, 2023, 38(12): 1086-1090.
[9]	Li Lisha, Shen Xianghui, Liu Yanhui, Ren Yanbin. Aortic root anatomy and atrial septal mobility analyzed by transesophageal echocardiography [J]. Clinical Focus, 2023, 38(11): 1012-1015.
[10]	Li Zhiyong. Transient peripheral carotid inflammation syndrome diagnosed by ultrasonography: A case report and literature review [J]. Clinical Focus, 2023, 38(11): 1027-1030.
[11]	Xu Yang, Xue Ling. Influencing factors for mild cognitive impairment in type H hypertension patients combined with type 2 diabetes mellitus [J]. Clinical Focus, 2023, 38(10): 887-892.
[12]	Zhang Yongzhi, Li Yanmin, Ma Xiaowen, Gu Ping. Aortic dissection with weakness and numbness of both lower limbs as the first manifestation: A case report and literature review [J]. Clinical Focus, 2023, 38(10): 912-916.
[13]	Wang Jiaqi, Xie Yuetao, Gao Man, Song Xuelian, Zhang Feifei, Dang Yi, Qi Xiaoyong. Treatment of variant angina pectoris guided by the optical coherence tomography: A case report and literature review [J]. Clinical Focus, 2023, 38(10): 917-921.
[14]	Yang Changlin, Cao Shufeng, Qiao Lian, Zhao Huimin. Type I Kounis syndrome caused by drug allergy: A case report [J]. Clinical Focus, 2023, 38(10): 922-925.
[15]	Duan Fang, Cui Wei. Application principles of vasodilators in the treatment of acute heart failure [J]. Clinical Focus, 2023, 38(9): 773-778.